{"id":3693,"date":"2026-09-16T13:04:18","date_gmt":"2026-09-16T13:04:18","guid":{"rendered":"https:\/\/drsoniafawad.com\/?p=3693"},"modified":"2026-09-16T13:04:18","modified_gmt":"2026-09-16T13:04:18","slug":"lifestyle-change-plus-drugs-may-prevent-masld-in-type-2-diabetes","status":"publish","type":"post","link":"https:\/\/drsoniafawad.com\/?p=3693","title":{"rendered":"Lifestyle change plus drugs may prevent MASLD in type 2 diabetes"},"content":{"rendered":"<p><br \/>\n<\/p>\n<div data-component=\"ArticleContent\">\n<div class=\"article__below-title\">\n<div class=\" article__posted-date\">\n<p>September 16, 2026<\/p>\n<p>3 min read<\/p>\n<\/p><\/div>\n<div class=\"mobile-trust-box\">\n<div class=\"row\">\n<div class=\"col-12 col-md-5 d-xl-none\">\n<div class=\"trust-box\">\n<div class=\"trust-box-logo d-none d-md-block\">\n            <img decoding=\"async\" src=\"https:\/\/www.healio.com\/~\/media\/h5\/feature\/news\/publogos\/et.svg?la=en&amp;h=23&amp;w=148&amp;hash=7DBE65E47ABE522DBAC4A3C80BB97B4E\" class=\"logo-img\" height=\"23\" alt=\"endocrine today logo\" width=\"148\"\/>\n          <\/div>\n<\/p><\/div>\n<\/p><\/div>\n<div class=\"col-12 col-md-6 offset-md-1 offset-xl-0 col-xl-12\">\n<div class=\"email-alert-button-wrapper d-none\" data-component=\"EmailTopicAlert\" data-module=\"Subspecialty Email Topic Alerts Top\" data-manage-email-link=\"\/footer\/account-information\/my-account\/email-subscriptions-and-alerts#emailAlerts\">\n  <hidden data-setting-item=\"d265901d-6d37-49c7-a8f6-c7bf19a02509\"\/><br \/>\n  <hidden data-crm-source=\"Subspecialty Topic Alert\"\/><\/p>\n<div class=\"email-alert-button d-none\" data-topic-button=\"not-subscribed\">\n<p>&#13;<br \/>\n      <span data-module-track-action=\"Email Alerts TOP_Click_Healio News Article\" data-module-track-label=\"Email Alerts TOP_Healio News Article\">&#13;<br \/>\n        <i class=\"fas fa-plus-circle\"\/>&#13;<br \/>\n        Add topic to email alerts&#13;<br \/>\n      <\/span>&#13;\n    <\/p>\n<div class=\"email-alert-inner collapse uf1ab600e4df04b40b5a17be54a7acf78\">\n<div class=\"email-alert-dialogue\">\n<p>&#13;<br \/>\n          Receive an email when new articles are posted on <span data-content=\"topic-title\"\/>&#13;\n        <\/p>\n<div class=\"d-none\" data-sign-up-type=\"unknown\">\n          Please provide your email address to receive an email when new articles are posted on <span data-content=\"topic-title\"\/>.<\/p><\/div>\n<\/p><\/div>\n<p>      <button type=\"button\" class=\"btn btn-primary\" data-loading-text=\"Loading &lt;i class=\" fa=\"\" fa-spinner=\"\" fa-spin=\"\">&#8220;&#13;<br \/>\n              data-action=&#8221;subscribe&#8221;&gt;&#13;<br \/>\n        Subscribe&#13;<br \/>\n      <\/button>\n    <\/div>\n<\/p><\/div>\n<div class=\"d-none\" data-topic-modal=\"failed\">    <strong>We were unable to process your request. Please try again later. If you continue to have this issue please contact <a href=\"https:\/\/www.healio.com\/news\/endocrinology\/20260916\/mailto:customerservice@slackinc.com\">customerservice@slackinc.com<\/a>.<\/strong>  <\/p>\n<p><button data-dismiss=\"modal\" class=\"btn btn-primary btn-lg btn-block\">Back to Healio<\/button><\/p>\n<\/div>\n<\/div><\/div>\n<\/p><\/div>\n<\/p><\/div>\n<\/div>\n<h2>Key takeaways:<\/h2>\n<ul>\n<li>Adults with type 2 diabetes or prediabetes plus cardiometabolic risk factors should be screened for MASLD.<\/li>\n<li>Increased physical activity, dietary change and improved sleep may lower MASLD risk.<\/li>\n<\/ul>\n<p>Diabetes care and education specialists should identify people with diabetes at risk for  metabolic dysfunction-associated steatotic liver disease and intervene early in disease progression, according to two speakers. <\/p>\n<p>Metabolic dysfunction-associated steatotic liver disease (MASLD) is a <a rel=\"noopener noreferrer\" href=\"https:\/\/www.healio.com\/news\/endocrinology\/20260129\/pcos-and-masld-increase-cardiometabolic-risk-for-young-women\" id=\"rId9\" target=\"_blank\">common comorbidity<\/a> for people with diabetes. <b>Susan Cornell, PharmD, CDCES, <\/b><b>FAPhA<\/b><b>, FADCES,<\/b> professor emeritus at Midwestern University College of Pharmacy; diabetes care and education specialist and consultant at Bolingbrook Christian Health Center and Will Grundy Medical Clinic; and a Healio | Endocrine Today Editorial Board Member, said approximately 70% of people with type 2 diabetes and 20% of those with type 1 diabetes have MASLD. Additionally, Cornell said, about half of people with diabetes and MASLD will go on to develop metabolic dysfunction-associated steatohepatitis (MASH). <\/p>\n<figure class=\"figure article__og-image\">&#13;\n    <picture>&#13;<source srcset=\"https:\/\/www.healio.comhttps:\/\/www.healio.comhttps:\/\/www.healio.com\/~\/media\/slack-news\/endocrinology\/misc\/infographics\/2026\/09_september\/et0926warwick_adces_ig1.webp?w=476\" media=\"(max-width: 768px)\">&#13;<source srcset=\"https:\/\/www.healio.com\/~\/media\/slack-news\/endocrinology\/misc\/infographics\/2026\/09_september\/et0926warwick_adces_ig1.webp?w=800\" media=\"(max-width: 992px)\">&#13;<source srcset=\"https:\/\/www.healio.com\/~\/media\/slack-news\/endocrinology\/misc\/infographics\/2026\/09_september\/et0926warwick_adces_ig1.webp?w=595\" media=\"(max-width: 1200px)\">&#13;<source srcset=\"https:\/\/www.healio.comhttps:\/\/www.healio.comhttps:\/\/www.healio.com\/~\/media\/slack-news\/endocrinology\/misc\/infographics\/2026\/09_september\/et0926warwick_adces_ig1.webp?w=476\" media=\"(min-width: 1200px)\">&#13;<source srcset=\"https:\/\/www.healio.comhttps:\/\/www.healio.comhttps:\/\/www.healio.com\/~\/media\/slack-news\/endocrinology\/misc\/infographics\/2026\/09_september\/et0926warwick_adces_ig1.webp?w=476\">&#13;<br \/>\n&#13;<br \/>\n      <img decoding=\"async\" src=\"https:\/\/www.healio.com\/~\/media\/slack-news\/endocrinology\/misc\/infographics\/2026\/09_september\/et0926warwick_adces_ig1.jpg?w=800\" alt=\"Susan Cornell, PharmD, CDCES, FAPhA, FADCES\" class=\"figure-img img-fluid\" width=\"800\"\/>&#13;<br \/>\n    <\/source><\/source><\/source><\/source><\/source><\/picture>&#13;<figcaption class=\"figure-caption\">&#13;<br \/>\n      &#13;<br \/>\n    <\/figcaption>&#13;<br \/>\n  <\/figure>\n<p>During a talk at the Association of Diabetes Care &amp; Education Specialists annual meeting, Cornell and <b>Kathy Warwick, RDN, LDN, CDCES,<\/b> diabetes care and education specialist and owner of Professional Nutrition Consultants LLC, discussed the role diabetes care and education specialists can play in managing liver health for people with diabetes.<\/p>\n<p>\u201cThe liver now needs to be in our repertoire of screening events,\u201d Cornell said during a presentation. \u201cAlways remember lifestyle [intervention] is the cornerstone. Drugs are always added to lifestyle.\u201d<\/p>\n<p>There are several reasons screening for MASLD and MASH is so difficult, according to Warwick. She said the disease is typically asymptomatic for patients, though they may be experiencing degradations in health-related quality of life. Warwick said other barriers are a stigma surrounding perceived alcohol use, a MASLD diagnosis being downplayed by patients, or any symptoms being attributed to other cardiometabolic complications. <\/p>\n<p>Additionally, Warwick said, there is a lack of awareness about MASLD among healthcare professionals, a lack of standard guidelines for treating the disease, and only two FDA-approved medications for the condition: resmetirom (Rezdiffra, Madrigal Pharmaceuticals) and semaglutide (Wegovy, Novo Nordisk).<\/p>\n<p>\u201cA lot of physicians don\u2019t really know what to do with that diagnosis or what follows next,\u201d Warwick said. \u201cThe thing that\u2019s scary is that they give conflicting messages, the healthcare professionals, and then they are not even sure about the terminology. I see physicians still sending people to me and calling it nonalcoholic fatty liver disease.\u201d<\/p>\n<h2>Screening and lifestyle intervention<\/h2>\n<p>Warwick reviewed recommendations for <a rel=\"noopener noreferrer\" href=\"https:\/\/www.healio.com\/news\/gastroenterology\/20251030\/screening-surveillance-for-masld-needs-to-expand-beyond-bmi\" id=\"rId10\" target=\"_blank\">MASLD screening<\/a> from the American Diabetes Association 2026 Standards of Care. She said people with prediabetes or type 2 diabetes with obesity, cardiometabolic risk factors or established cardiovascular disease should be screened with the Fibrosis-4 (FIB-4) index. Screening should also occur among anyone with type 2 diabetes and an alanine aminotransferase level of more than 30 U\/L. Warwick said anyone who has a FIB-4 index of 1.3 or greater should undergo additional risk assessment, and adults at increased risk should be referred to a gastroenterologist or hepatologist for further evaluation and management. <\/p>\n<p>Warwick said lifestyle intervention is crucial for adults at risk for MASLD just as it is for those at risk for other cardiometabolic diseases. Some recommendations include a diet with reduced caloric intake, more plant-based foods, increasing intake of fiber, prebiotics and healthy fat sources and limiting saturated fat, added sugars, alcohol, processed meats and other processed foods. Diabetes care and education specialists should also have people with diabetes increase physical activity, ensure they are getting high-quality sleep, address any mental health concerns and eliminate nicotine exposure.<\/p>\n<p>\u201cIt\u2019s important to note that we focus so much on weight when, in fact, if they just reduce their calorie intake and they just increase their physical activity a little bit, you see improvement in [liver fat],\u201d Warwick said. \u201cWe don\u2019t need to set impossible goals for those clients. We just need to see if we can get them moving a little bit and we just need to make them aware of the fact that if they just reduce their caloric intake a bit, they can see improvement.\u201d<\/p>\n<h2>Medications for MASLD<\/h2>\n<p>Cornell said there are three goals of pharmacotherapy for adults with type 2 diabetes at high risk for MASLD:<\/p>\n<ul>\n<li>cardiorenal risk reduction;<\/li>\n<li>achieving and maintaining glycemic and weight goals; and<\/li>\n<li>mitigating risk for MASLD or MASH.<\/li>\n<\/ul>\n<p>Among medications that could be prescribed in these patients are incretin-based therapies such as <a rel=\"noopener noreferrer\" href=\"https:\/\/www.healio.com\/news\/gastroenterology\/20260617\/glp1s-may-nearly-halve-risk-for-hepatic-complications-in-masld-type-2-diabetes\" id=\"rId11\" target=\"_blank\">GLP-1 receptor agonists<\/a> or GLP-1\/glucose-dependent insulinotropic polypeptide (GIP) dual agonists. Semaglutide is the only incretin-based drug currently approved for MASLD, but healthcare professionals should not rule out other therapies, Cornell said.  <\/p>\n<p>\u201cThere are studies ongoing with other GLP-1s, and even in the Obesity Association guidelines, they\u2019re saying that there is potential benefit with liraglutide (Saxenda\/Victoza, Novo Nordisk) and tirzepatide (Mounjaro\/Zepbound, Eli Lilly),\u201d Cornell said. \u201cOne of the things we want to think about from a medication standpoint is double dipping. Can we treat more than one condition with one drug?\u201d<\/p>\n<p>Other options include pioglitazone, which can reduce hepatic steatosis and inflammation and increase insulin uptake in peripheral tissue; SGLT2 inhibitors, which can decrease hepatic fat and improve cardiometabolic parameters; and resmetirom, which can improve lipid metabolism and lower fat accumulation and liver inflammation.<\/p>\n<p>Cornell said patients should not be treated with medications alone, and that drugs must be used in conjunction with lifestyle intervention.<\/p>\n<p>\u201cMedicine is always added to lifestyle,\u201d Cornell said. \u201cBecause [patients] are so focused on glucose, they forget about the benefits to the heart, the kidneys and the liver. [We are] just reminding them that there\u2019s more involved than your sugar.\u201d<\/p>\n<div class=\"article__content--footer\">\n<div class=\"publisher-logo\">\n    <span>Published by:<\/span><br \/>\n    <img decoding=\"async\" src=\"https:\/\/www.healio.com\/~\/media\/h5\/feature\/news\/publogos\/et.svg?la=en&amp;h=23&amp;w=148&amp;hash=7DBE65E47ABE522DBAC4A3C80BB97B4E\" class=\"logo-img\" height=\"23\" alt=\"endocrine today logo\" width=\"148\"\/>\n  <\/div>\n<div class=\"sources-references-disclosures\">\n<h3>Sources\/Disclosures<\/h3>\n<h2> Source: <\/h2>\n<p class=\"citation\">Warwick K, et al. Presentation D01. Presented at: ADCES26; Aug. 7-10, 2026; Columbus, Ohio.<\/p>\n<div class=\"disclosures\">\n<p>&#13;<br \/>\n        <strong> Disclosures: <\/strong>&#13;<br \/>\n        Cornell reports advising for Novo Nordisk and speaking for Boehringer Ingelheim. Warwick reports no relevant financial disclosures.&#13;\n      <\/p>\n<\/p><\/div>\n<\/div>\n<p><!-- Healio AI Widget --><\/p>\n<div class=\"healio-ai-component-inline\" data-no-ads=\"true\" data-module-track-category=\"Healio AI\" data-module-track-action=\"Click\" data-module-track-label=\"Access Healio Ai from component - News_AI Component - In-Content (all devices)\">\n<div class=\"healio-ai-content\">\n    <img decoding=\"async\" src=\"https:\/\/m3.healio.com\/~\/media\/images\/healio-ai\/healio-ai_logo.svg\" alt=\"Healio AI\" class=\"healio-ai-logo\"\/><\/p>\n<p><strong>Ask a clinical question<\/strong> and tap into <strong>Healio AI&#8217;s knowledge<\/strong> base.<\/p>\n<ul>&#13;<\/p>\n<li>PubMed, enrolling\/recruiting trials, guidelines<\/li>\n<p>&#13;<\/p>\n<li>Clinical Guidance, Healio CME, FDA news<\/li>\n<p>&#13;<\/p>\n<li>Healio&#8217;s exclusive daily news coverage of clinical data<\/li>\n<p>&#13;\n    <\/ul>\n<p>    <button class=\"healio-ai-button\" onclick=\"window.location.href=\" https:=\"\">Learn more<\/button>\n  <\/div>\n<\/div>\n<div class=\"email-alert-button-wrapper d-none\" data-component=\"EmailTopicAlert\" data-module=\"Subspecialty Email Topic Alerts Top\" data-manage-email-link=\"\/footer\/account-information\/my-account\/email-subscriptions-and-alerts#emailAlerts\">\n  <hidden data-setting-item=\"d265901d-6d37-49c7-a8f6-c7bf19a02509\"\/><br \/>\n  <hidden data-crm-source=\"Subspecialty Topic Alert\"\/><\/p>\n<div class=\"email-alert-button d-none\" data-topic-button=\"not-subscribed\">\n<p>&#13;<br \/>\n      <span data-module-track-action=\"Email Alerts TOP_Click_Healio News Article\" data-module-track-label=\"Email Alerts TOP_Healio News Article\">&#13;<br \/>\n        <i class=\"fas fa-plus-circle\"\/>&#13;<br \/>\n        Add topic to email alerts&#13;<br \/>\n      <\/span>&#13;\n    <\/p>\n<div class=\"email-alert-inner collapse uf1ab600e4df04b40b5a17be54a7acf78\">\n<div class=\"email-alert-dialogue\">\n<p>&#13;<br \/>\n          Receive an email when new articles are posted on <span data-content=\"topic-title\"\/>&#13;\n        <\/p>\n<div class=\"d-none\" data-sign-up-type=\"unknown\">\n          Please provide your email address to receive an email when new articles are posted on <span data-content=\"topic-title\"\/>.<\/p><\/div>\n<\/p><\/div>\n<p>      <button type=\"button\" class=\"btn btn-primary\" data-loading-text=\"Loading &lt;i class=\" fa=\"\" fa-spinner=\"\" fa-spin=\"\">&#8220;&#13;<br \/>\n              data-action=&#8221;subscribe&#8221;&gt;&#13;<br \/>\n        Subscribe&#13;<br \/>\n      <\/button>\n    <\/div>\n<\/p><\/div>\n<div class=\"d-none\" data-topic-modal=\"failed\">    <strong>We were unable to process your request. Please try again later. If you continue to have this issue please contact <a href=\"https:\/\/www.healio.com\/news\/endocrinology\/20260916\/mailto:customerservice@slackinc.com\">customerservice@slackinc.com<\/a>.<\/strong>  <\/p>\n<p><button data-dismiss=\"modal\" class=\"btn btn-primary btn-lg btn-block\">Back to Healio<\/button><\/p>\n<\/div>\n<\/div><\/div>\n<\/p><\/div>\n<p><br \/>\n<br \/><a href=\"https:\/\/www.healio.com\/news\/endocrinology\/20260916\/combine-lifestyle-change-with-drugs-for-people-with-type-2-diabetes-at-risk-for-masld\">Source link <\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>September 16, 2026 3 min read &#13; &#13; &#13; Add topic to email alerts&#13; &#13; &#13; Receive an email when new articles are posted on &#13; Please provide your email address to receive an email when new articles are posted on . &#8220;&#13; data-action=&#8221;subscribe&#8221;&gt;&#13; Subscribe&#13; We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Back to Healio Key takeaways: Adults with type 2 diabetes or prediabetes plus cardiometabolic risk factors should be screened for MASLD. Increased physical activity, dietary change and improved sleep may lower MASLD risk. Diabetes care and education specialists should identify people with diabetes at risk for metabolic dysfunction-associated steatotic liver disease and intervene early in disease progression, according to two speakers. Metabolic dysfunction-associated steatotic liver disease (MASLD) is a common comorbidity for people with diabetes. Susan Cornell, PharmD, CDCES, FAPhA, FADCES, professor emeritus at Midwestern University College of Pharmacy; diabetes care and education specialist and consultant at Bolingbrook Christian Health Center and Will Grundy Medical Clinic; and a Healio | Endocrine Today Editorial Board Member, said approximately 70% of people with type 2 diabetes and 20% of those with type 1 diabetes have MASLD. Additionally, Cornell said, about half of people with diabetes and MASLD will go on to develop metabolic dysfunction-associated steatohepatitis (MASH). &#13; &#13;&#13;&#13;&#13;&#13;&#13; &#13; &#13; &#13;&#13; &#13; &#13; During a talk at the Association of Diabetes Care &amp; Education Specialists annual meeting, Cornell and Kathy Warwick, RDN, LDN, CDCES, diabetes care and education specialist and owner of Professional Nutrition Consultants LLC, discussed the role diabetes care and education specialists can play in managing liver health for people with diabetes. \u201cThe liver now needs to be in our repertoire of screening events,\u201d Cornell said during a presentation. \u201cAlways remember lifestyle [intervention] is the cornerstone. Drugs are always added to lifestyle.\u201d There are several reasons screening for MASLD and MASH is so difficult, according to Warwick. She said the disease is typically asymptomatic for patients, though they may be experiencing degradations in health-related quality of life. Warwick said other barriers are a stigma surrounding perceived alcohol use, a MASLD diagnosis being downplayed by patients, or any symptoms being attributed to other cardiometabolic complications. Additionally, Warwick said, there is a lack of awareness about MASLD among healthcare professionals, a lack of standard guidelines for treating the disease, and only two FDA-approved medications for the condition: resmetirom (Rezdiffra, Madrigal Pharmaceuticals) and semaglutide (Wegovy, Novo Nordisk). \u201cA lot of physicians don\u2019t really know what to do with that diagnosis or what follows next,\u201d Warwick said. \u201cThe thing that\u2019s scary is that they give conflicting messages, the healthcare professionals, and then they are not even sure about the terminology. I see physicians still sending people to me and calling it nonalcoholic fatty liver disease.\u201d Screening and lifestyle intervention Warwick reviewed recommendations for MASLD screening from the American Diabetes Association 2026 Standards of Care. She said people with prediabetes or type 2 diabetes with obesity, cardiometabolic risk factors or established cardiovascular disease should be screened with the Fibrosis-4 (FIB-4) index. Screening should also occur among anyone with type 2 diabetes and an alanine aminotransferase level of more than 30 U\/L. Warwick said anyone who has a FIB-4 index of 1.3 or greater should undergo additional risk assessment, and adults at increased risk should be referred to a gastroenterologist or hepatologist for further evaluation and management. Warwick said lifestyle intervention is crucial for adults at risk for MASLD just as it is for those at risk for other cardiometabolic diseases. Some recommendations include a diet with reduced caloric intake, more plant-based foods, increasing intake of fiber, prebiotics and healthy fat sources and limiting saturated fat, added sugars, alcohol, processed meats and other processed foods. Diabetes care and education specialists should also have people with diabetes increase physical activity, ensure they are getting high-quality sleep, address any mental health concerns and eliminate nicotine exposure. \u201cIt\u2019s important to note that we focus so much on weight when, in fact, if they just reduce their calorie intake and they just increase their physical activity a little bit, you see improvement in [liver fat],\u201d Warwick said. \u201cWe don\u2019t need to set impossible goals for those clients. We just need to see if we can get them moving a little bit and we just need to make them aware of the fact that if they just reduce their caloric intake a bit, they can see improvement.\u201d Medications for MASLD Cornell said there are three goals of pharmacotherapy for adults with type 2 diabetes at high risk for MASLD: cardiorenal risk reduction; achieving and maintaining glycemic and weight goals; and mitigating risk for MASLD or MASH. Among medications that could be prescribed in these patients are incretin-based therapies such as GLP-1 receptor agonists or GLP-1\/glucose-dependent insulinotropic polypeptide (GIP) dual agonists. Semaglutide is the only incretin-based drug currently approved for MASLD, but healthcare professionals should not rule out other therapies, Cornell said. \u201cThere are studies ongoing with other GLP-1s, and even in the Obesity Association guidelines, they\u2019re saying that there is potential benefit with liraglutide (Saxenda\/Victoza, Novo Nordisk) and tirzepatide (Mounjaro\/Zepbound, Eli Lilly),\u201d Cornell said. \u201cOne of the things we want to think about from a medication standpoint is double dipping. Can we treat more than one condition with one drug?\u201d Other options include pioglitazone, which can reduce hepatic steatosis and inflammation and increase insulin uptake in peripheral tissue; SGLT2 inhibitors, which can decrease hepatic fat and improve cardiometabolic parameters; and resmetirom, which can improve lipid metabolism and lower fat accumulation and liver inflammation. Cornell said patients should not be treated with medications alone, and that drugs must be used in conjunction with lifestyle intervention. \u201cMedicine is always added to lifestyle,\u201d Cornell said. \u201cBecause [patients] are so focused on glucose, they forget about the benefits to the heart, the kidneys and the liver. [We are] just reminding them that there\u2019s more involved than your sugar.\u201d Published by: Sources\/Disclosures Source: Warwick K, et al. Presentation D01.<\/p>\n","protected":false},"author":1,"featured_media":3694,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-3693","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/drsoniafawad.com\/index.php?rest_route=\/wp\/v2\/posts\/3693","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/drsoniafawad.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/drsoniafawad.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/drsoniafawad.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/drsoniafawad.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=3693"}],"version-history":[{"count":0,"href":"https:\/\/drsoniafawad.com\/index.php?rest_route=\/wp\/v2\/posts\/3693\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/drsoniafawad.com\/index.php?rest_route=\/wp\/v2\/media\/3694"}],"wp:attachment":[{"href":"https:\/\/drsoniafawad.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=3693"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/drsoniafawad.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=3693"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/drsoniafawad.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=3693"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}